Our group is focused on the development of novel diagnostic and therapeutic approaches for the treatment of patients with genitourinary (GU) cancers, which includes prostate, bladder, and kidney cancer among others. Our approach involves the retrospective development of candidate prognostic and predictive biomarkers utilizing a comprehensive clinical database and specimen biorepository along with prospective validation of these biomarkers in clinical trials. By combining mechanism-based molecular markers with novel therapeutics, our ultimate goal is to ultimately enhance the care of patients with genitourinary malignancies by maximizing the likelihood of benefit from treatment while minimizing the risk of adverse events.
Genitourinary (GU) Cancer Research Program
GU Cancer Database: Creating and maintaining a high quality database and GU tumor bank in which clinical data and biological specimens are collected and stored to support basic and translational research
Predicting Response to Platinum Chemotherapy in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Using a Genomic Signature for ‘BRCA-ness’: 1) Identify a clinical and pathologic phenotype of men with prostate cancers which express a ‘BRCA-ness’ signature base on known germline BRCA1 and 2 breast cancers 2) Conduct a prospective trial of oral satraplatin as second-line chemotherapy for metastatic CRPC and correlate response and survival to the ‘BRCAness’ signature.
Multi-center Phase IB/II Trial of Gemcitabine, Cisplatin, Plus Lenalidomide As First-Line Therapy for Patients with Metastatic Urothelial Carcinoma: Determine the recommended dose of the combination of gemcitabine, cisplatin, plus lenalidomide in patients with metastatic urothelial carcinoma and evaluate the activity of this regimen as determined by the objective response rate.
Multi-center Phase II Trial of Single-Agent Amrubicin as Second-Line Therapy in Patients with Advanced/Metastatic Refractory Urothelial Carcinoma: Determine the objective response rate to treatment with amrubicin.
This project is establishing a large retrospective database detailing the care of patients with advanced bladder cancer (and other cancers of the urothelial tract) for the purposes of:
- Generating insights regarding patterns of care
- Exploring prognostic and predictive variables
- Informing future clinical trial design
- Performing comparative effectiveness analyses
- Assessing the impact of comorbidities on patient outcomes
Each of these analyses will be used to enhance the care of future patients with cancers of the bladder (and other cancers of the urothelial tract). RISC is an international, multi-center, collaborative effort with Mount Sinai functioning as the data coordinating center.
Steering Committee
Matthew D. Galsky, MD, Icahn School of Medicine/Tisch Cancer Institute
Jonathan Rosenberg, MD, Harvard Medical School/Dana-Farber Cancer Institute
Joaquim Bellmunt, MD, University Hospital Del Mar-IMIM
Toni Choueiri, MD, Harvard Medical School/Dana-Farber Cancer Institute
Thomas Powles, MD, Barts and London School of Medicine
Noah Hahn, MD, Indiana University/Simon Cancer Center
Robert Dreicer, MD, Cleveland Clinic/Taussig Cancer Center
Guru Sonpavde, MD, Texas Oncology/US Oncology
Cora Sternberg, MD, San Camillo Forlanini Hospital
Yu-Ning Wong, MD, Fox Chase Cancer Center
William K. Oh, MD, Icahn School of Medicine/Tisch Cancer Institute
Icahn School of Medicine Staff
Steven Grossman, Clinical Research Supervisor, Icahn School of Medicine/Tisch Cancer Institute
Tiffany Yee, Clinical Research Coordinator, Icahn School of Medicine/Tisch Cancer Institute
Ryan Hendricks, Clinical Research Coordinator, Icahn School of Medicine/Tisch Cancer Institute
William K. Oh, MD
Chief, Division of Hematology and Medical Oncology
Professor of Medicine and Urology
Ezra M. Greenspan, MD Professor in Clinical Cancer Therapeutics
Icahn School of Medicine
Associate Director of Clinical Research
The Tisch Cancer Institute
Carol Saenz
Executive Assistant to Dr. Oh
Division of Hematology and Medical Oncology
Icahn School of Medicine
The Tisch Cancer Institute
Matthew D. Galsky, MD
Director, Genitourinary Medical Oncology
Associate Medical Director, Cancer Clinical Trials Office
Mount Sinai Health System
The Tisch Cancer Institute
Frances Soto
Administrative Assistant to Dr. Galsky
Division of Hematology and Medical Oncology
Icahn School of Medicine
The Tisch Cancer Institute
Che-kai Tsao, MD
Assistant Professor, Division of Hematology and Medical Oncology
Icahn School of Medicine
The Tisch Cancer Institute
Colleen De Boer, RN, MSN, ANP-BC
Nurse Practitioner
GU Medical Oncology
The Tisch Cancer Institute
Gina McKiernan
Administrative Assistant
Division of Hematology/Medical Oncology
Icahn School of Medicine
Lan He
Senior Associate Researcher
Hematology/Oncology
The Tisch Cancer Institute
Yixuan Gong, PhD
Senior Scientist Department of Medical Oncology/Hematology
The Tisch Cancer Institute
Steven Grossman, MA
Clinical Research Supervisor
Genitourinary Research Program
Icahn School of Medicine
The Tisch Cancer Institute
Diana Aristizabal
Clinical Research Nurse, BSN-MSN
The Tisch Cancer Institute
Beth Inserra
Clinical Research Coordinator
Hematology/Oncology
The Tisch Cancer Institute
Tiffany Yee
Clinical Research Coordinator
Hematology/Oncology
The Tisch Cancer Institute
Ryan Hendricks
Clinical Research Coordinator
Hematology/Oncology
The Tisch Cancer Institute
Click on the names below to view faculty profiles, including publications:
2012 New York Magazine “Top Doctors 2012”
2011 New York Magazine “Top Doctors 2011”
2011 Election to the American Society of Clinical Investigation (ASCI)
2011-present America’s Top Doctors (Castle Connolly)
2011-present New York Super Doctors
2010 Excellence in Grand Rounds, Department of Medicine, MSSM
2010 New York Magazine “Top Doctors 2011”
2009-present Top Doctors: New York Metro Edition (Castle Connolly)
2008-2009 Patients Choice Award (vitals.com)
2009 Boston Magazine “Top Doctors”
2008-present America’s Top Doctors for Cancer (Castle Connolly)
2007-2008 Brigham/Harvard Business School Physician Leadership Program
2005 Boston Magazine “Top Doctors”
2004-present Marquis Who’s Who in America
2004 Award Recipient, Loan Repayment Program for Clinical Research, NIH
2003-present Best Doctors in America
2003 Compassionate Caregiver of the Year, Kenneth B. Schwartz Center, Honorable Mention
2002-2003 Dunkin Donuts Rising Stars Award
1997 ASCO/AACR Methods in Clinical Cancer Research Workshop
1992 Election to Alpha Omega Alpha
1992 Prize in Internal Medicine, NYU School of Medicine
2011 Junior Faculty Outstanding Teaching Award – Icahn School of Medicine
2011 Tisch Cancer Institute Hematology/Oncology Fellowship Program
2009-2010 American Society of Clinical Oncology Leadership Development Program
2009 American Society of Clinical Oncology Clinical Trials Participation Award (accepted on behalf of Comprehensive Cancer Centers of Nevada)
2003 American Society of Clinical Oncology Merit Award
1998 Leon Levinson Prize (Tufts School of Medicine, Excellence in Physiology)
1998 Medical Class of 1928 Award (Tufts School of Medicine, Excellence in Anatomy
1997 Alpha Omega Alpha Honor Society
2012 Mount Sinai Hospital, Fellow Physician of the Year
2012 ASCO Merit Award
2012 ASCO Genitourinary Cancer Symposium Merit Award
2011 ASCO/AACR Workshop on Methods in Clinical Cancer Research
2011 ASCO Oncology Trainee Award
2011 Chief Fellow Appointment, Hematology and Medical Oncology Fellowship
2000 Cum Laude, Mathematics and Economics, New York University
Peer Reviewed Original Contributions:
1. Nelson JB, Chen RN, Bishoff JT, Oh WK, Kantoff PW, Donehower RC, Kavoussi LR Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular tumors. Urology. 1999; 54(6):1064-7.
2. Smith MR, Kantoff PW, Oh WK, Elson G, Manola J, McMullin M, Jacobsen J, Brufsky A, Kaufman D. Phase II trial of the antiestrogen toremifene for androgen-independent prostate cancer. The Prostate Journal 1999; 1(4):185-9.
3. Oh WK, Manola J, Richie JR, Loughlin KR, Kantoff PK. A phase II trial of methotrexate, cisplatin, 5-FU, and leucovorin in the treatment of invasive and metastatic urothelial cancer. Cancer 1999; 86:1329-34.
4. Oh WK, Kantoff PW. Locally advanced prostate cancer: is chemotherapy the next step? J Clin Oncol 1999; 17:3664-75.
5. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Friedlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh WK, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Vollmer R, Wilding G. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the PSA Working Group. J Clin Oncol 1999; 17:3461-67.
6. Oh WK, Manola J, Renshaw AA, Brodkin D, Loughlin KR, Richie JP, Shapiro CL, Kantoff PW. Smoking and alcohol use may be risk factors for worse outcome in clear cell renal carcinoma. Urology 2000; 55:31-35.
7. Oh WK, Lee BL, Sweitzer NK. Nonmalignant diagnoses in patients. Case 3. Right atrial thrombus associated with a central venous catheter in a patient with metastatic adrenocortical carcinoma. J Clin Oncol 2000; 18:2639-9.
8. Kaufman D, Raghavan D, Carducci M, Levine EG, Murphy B, Aisner J, Kuzel T, Nicol S, Oh W, Stadler W. Phase II trial of gemcitabine plus cisplatin in patients with metastatic urothelial cancer. J Clin Oncol 2000; 18:1921-1927.
9. Eder JP, Kantoff PW, Roper K, Xu GX, Bubley GJ, Boyden J, Gritz L, Mazzara G, Oh WK, Arlen P, Tsang KY, Panicali D, Schlom J, Kufe DW. A phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin Cancer Res 2000; 6:1632-8.
10. Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman D, Oh WK, Demetri G, Figg W, Spiegelman BM, Kantoff PW. Effects of ligand activation of PPAR gamma on human prostate cancer. Proc Natl Acad Sci USA 2000; 97:10990-5.
11. Smith MR, Kaufman D, Guerin K, Makatsoris T, Berlin S, Jacobsen J, Manola J, Oh WK, Kantoff PW. Phase II study of vinorelbine and estramustine for androgen-independent prostate cancer. Cancer 2000; 89:1824-1828.
12. Kelly WK, Curley T, Slovin S, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, Smith M, George D, Oh WK, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H. Paclitaxel, estramustine phosphate and carboplatin (TEC) in patients with advanced prostate cancer. J Clin Oncol 2000; 19:44-53.
13. Oh WK, George DJ, Hackmann K, Manola J, Kantoff PW. Activity of the herbal combination, PC-SPES, in the treatment of patients with androgen-independent prostate cancer. Urology 2001; 57:122-6.
14. Oh WK, Manola J, George DJ, Fierman A, Fontaine-Rothe P, Prisby J, Morrissey S, Kaufman DW, Kantoff PW, Smith MR. A phase II trial of interferon-alpha and toremifene in advanced renal cell carcinoma. Cancer Investigation 2002; 20(2):186-191.
15. Oh WK, George DJ, Kantoff PW. Rapid rise in serum prostate specific antigen after discontinuation of the herbal therapy, PC-SPES: report of four cases. Cancer 2002; 94(3):686-9.
16. Oh WK, Loda M, Kantoff PW, Janicek M. Progessive sclerosis of isolated foot metastasis of prostate cancer. J Urol 2002; 167(3):1392.
17. D’Amico AV, Saegart T, Chen M, Renshaw AA, George DJ, Oh WK, Kantoff PW. Initial decline in hemoglobin during neoadjuvant hormonal therapy predicts for early PSA failure following radiation and hormonal therapy for patients with intermediate and high risk prostate cancer. Cancer 2002; 95(2):275-80.
18. Smith MR, Kaufman D, George D, Oh WK, Kazanis M, Manola J, Kantoff PW. Selective aromatase inhibition for patients with androgen-independent prostate carcinoma. Cancer 2002; 95(9):1864-8.
19. Oh WK, Tully P, Kantoff PW, Regan MM. Physician attitudes toward cytotoxic chemotherapy use in advanced prostate cancer. Cancer 2003; 97(9):2171-9.
20. Oh WK, Kaplan ID, Febbo PG, Prisby J, Manola J, Kaufman DS, Kantoff PW. Neoadjuvant Doxil chemotherapy prior to androgen ablation plus radiotherapy for high risk localized prostate cancer: feasibility and toxicity. Am J Clin Oncol 2003; 26(3):312-6.
21. Michaelson MD, Kaufman DS, Oh WK. Transitional cell carcinoma of the upper uroepithelial tract. Clinical Advances in Hematology & Oncology 2003; 1(2):102-4.
22. Oh WK, Manola J, Bittmann L, Brufsky A, Kaplan ID, Smith MR, Kaufman DS, Kantoff PW. Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology 2003; 62(1):99-104.
23. Bhayani SB, Ong A, Oh WK, Kantoff PW, Kavoussi LR. Laparoscopic retroperitoneal lymph node dissection for clinical stage I nonseminomatous germ cell testicular cancer: a long-term update. Urology 2003; 62(2):324-7.
24. Leibowitz SL, Oh WK. Overtreatment of a patient with presumed recurrent prostate cancer based on false-positive prostate specific antigen results. J Urol 2003; 170(4):1305.
25. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Small EJ. A phase II study of estramustine, docetaxel and carboplatin with granulocyte-colony-stimulating-factor support in patients with hormone refractory prostate carcinoma: Cancer and Leukemia Group B 99813. Cancer 2003; 98(12):2592-8.
26. Leibowitz SB, Garber JE, Fox EA, Loda M, Kaufman DS, Kantoff PW, Oh WK. Male patients with diagnoses of both breast cancer and prostate cancer. Breast J 2003; 9(3):208-12.
27. Liu G, Gandara DR, Lara PN, Raghavan D, Doroshow JH, Twardowski P, Kantoff P, Oh W, Kim K, Wilding G. A phase II trial of flavopiridol (NSC# 649890) in patients with previously untreated metastatic androgen-independent prostate cancer. Clin Cancer Res 2004; 10(3):924-8.
28. George DJ, Regan MM, Oh WK, Tay MH, Manola J, Decalo N, Duggan S, DeWolf WC, Kantoff PW, Bubley GJ. Radical prostatectomy lowers plasma vascular endothelial growth factor levels in patients with prostate cancer. Urology 2004; 63(2):327-32
29. Tay MH, Kaufman DS, Regan MM, Leibowitz SB, George DJ, Febbo PG, Manola J, Smith MR, Kaplan ID, Kantoff PW, Oh WK. Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Ann Oncol 2004; 15(6):974-8.
30. Abe M, Manola J, Oh WK, Parslow D, George D, Austin C, Kantoff P. Plasma levels of heat shock protein 70 (Hsp70) in prostate cancer patients: a potential biomarker for prostate cancer. Clin Prostate Cancer 2004; 3(1):49-53.
31. Oh WK, Kantoff PW, WeinbergV, Jones G, Rini BI, Derynck MK, BokR, Smith MR, Bubley GJ, Rosen RT, DiPaola RS, Small EJ. A prospective, multicenter, randomized phase II trial of the herbal supplement, PC-SPES, and diethylstilbestrol in patients with androgen-independent prostate cancer. J Clin Oncol 2004; 22(18):3705-12.
32. Kaufman DS, Carducci MA, Kuzel TM, Todd MB, Oh WK, Smith MR, Nicol SJ, Stadler WM. A multi-institutional phase II trial of gemcitabine plus paclitaxel in patients with locally advanced or metastatic urothelial cancer. Urol Oncol 2004; 22(5):393-7.
33. Smith MR, Manola J, Kaufman DS, George D, Oh WK, Mueller E, Slovin S, Speigelman B, Small E, Kantoff PW. Rosiglitazone versus placebo for men with prostate cancer and a rising serum prostate specific antigen after radical prostatectomy and/or radiation therapy. Cancer 2004; 101(7):1569-74.
34. Oh WK, Hagmann E, Manola J, George DJ, Gilligan TD, Jacobson JO, Smith MR, Kaufman DS, Kantoff PW. A phase I study of estramustine, weekly docetaxel and carboplatin chemotherapy in patients with hormone refractory prostate cancer. Clin Cancer Res 2005; 11(1):284-9.
35. Galsky MD, Small EJ, Oh WK, Chen I, Smith DC, Colevas AD, Martone L, Curley T, Delacruz A, Scher HI, Kelly WK. Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer. J Clin Oncol 2005; 23(7):1439-46.
36. Nakabayashi M, Regan MM, Lifsey D, Austin C, Kantoff PW, Taplin ME, Sartor O, Oh WK. Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer. BJU Int 2005; 96(6):783-6.
37. Febbo PW, Richie JP, George DJ, Loda M, Manola J, Shankar S, Barnes AS, Tempany C, Catalona W, Kantoff PW, Oh WK. Neoadjuvant docetaxel prior to radical prostatectomy in patients with high risk localized prostate cancer. Clin Cancer Res 2005; 11(14):5233-40.
38. Oh WK, George DJ, Tay, MH. Response to docetaxel plus carboplatin in hormone refractory prostate cancer patients who are not responding to taxane-based chemotherapy. Clin Prostate Cancer 2005; 4(1):61-4.
39. Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma: second line taxane-based therapy after first-line epothilone-B analog ixabepilone (BMS-247550) therapy. Cancer 2006; 106(1):58-62.
40. Nakabayashi M, Beard C, Kelly SM, Carr-Locke DL, Oh WK. Treatment of a radiation-induced rectal ulcer with hyperbaric oxygen therapy in a man with prostate cancer. Urologic Oncology 2006; 24(6):503-8.
41. Daskivich TD, Oh WK. Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: Insight into mechanisms? Urology 2006; 67:1084.e15-17.
42. Febbo PG, Thorner A, Rubin M, Loda M, Kantoff PW, Oh WK, Golub T, George D. The application of oligonucleotide microarrays to assess the biological effects of neoadjuvant imatinib mesylate treatment for localized prostate cancer. Clin Cancer Res 2006; 12(1):152-8.
43. Nakabayashi M, Bartlett D, Oh WK. Treatment of bicalutamide-induced gynecomastia with breast reduction surgery in a man with prostate cancer. J Clin Oncol 2006; 24(18):2958-9.
44. Oh WK, Manola J, Babcic V, Harnam N, Kantoff PW. Response to second-line chemotherapy in patients with hormone refractory prostate cancer receiving two sequences of mitoxantrone and taxanes. Urology 2006; 67(6):1235-40.
45. Smith MR, Manola J, Kaufman D, Oh WK, Bubley G, Kantoff PW. Celecoxib versus placebo for men with prostate cancer and a rising serum prostate specific antigen after radical prostatectomy and/or radiation therapy. J Clin Oncol 2006; 24(18):2723-8.
46. Michaelson MD, Kaufman DS, Kantoff PW, Oh WK, Smith MR. Randomized phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006; 107(3):530-5.
47. Nakabayashi M, Xie W, Regan MM, Jackman DM, Kantoff PW, Oh WK. Response to low-dose ketoconazole and subsequent dose escalation to high-dose ketoconazole in patients with androgen-independent prostate cancer. Cancer 2006; 107(5):975-81.
48. Daskivich TD, Regan MM, Oh WK. Prostate specific antigen doubling time calculation: Not as easy as 1, 2, 4. J Urol 2006; 176(5):1927-37
49. Oh WK, Hayes J, Evan C, Manola J, George DJ, Waldron H, Donovan M, Varner J, Orechia J, Katcher B, Lu D, Nevins A, Wright R, Tormey L, Talcott J, Rubin M, Loda M, Sellers WR, Richie JP, Kantoff PW*, Weeks JC*. Development of an integrated prostate cancer information system: Prostate CRIS. Clin Genitourin Cancer 2006; 5(1):61-6.
50. Oh WK, Proctor K, Nakabayashi M, Evan C, Tormey LK, Daskivich T, Antras L, Smith M, Neary MP, Duh MS. Risk of renal impairment in hormone refractory prostate cancer patients with bone metastases treated with zoledronic acid. Cancer 2007; 109(6):1090-1096.
51. Nakabayashi M*, Ling J*, Xie W, Regan MM, Oh WK. Response to vinorelbine with or without estramustine as second-line chemotherapy in patients with hormone refractory prostate cancer. Cancer J 2007; 13(2):125-129.
52. Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Kantoff PW, Beard C, Oh WK. Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer. J Urol 2007; 177(6):2146-50.
53. Daskivich TJ, Regan MM, Oh WK. Distinct prognostic role of prostate specific antigen doubling time and velocity at the emergence of androgen independence in patients treated with chemotherapy. Urology 2007; 70(3):527-31.
54. Avigan DE, Vasir D, George DJ, Oh WK, Atkins MB, McDermott DM, Kantoff PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007; 30(7):749-761
55. Xie W, Regan MM, Nakabayashi M, Oh WK. Higher prostate-specific antigen levels predict improved survival in men with bone metastatic hormone-refractory prostate cancer and normal alkaline phosphatase. Cancer 2007; 110(12):2709-15.
56. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson M, Wen S, Pagliaro LC, Tannir NM, Tu, SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis C. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 2007; 13(19):5816-24.
57. Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK. A phase II trial of docetaxel plus carboplatin in men with hormone-refractory prostate cancer who are refractory to docetaxel. Cancer 2008; 112(3):521-6.
58. Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn DK, Ross RW, Kantoff PW, Taplin ME, Oh WK. Response to docetaxel plus carboplatin-based chemotherapy as first and second line therapy in patients with metastatic hormone-refractory prostate cancer. BJU Int 2008; 101(3):308-12.
59. Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK. Efficacy of androgen deprivation therapy in patients with advanced prostate cancer: association between Gleason score, prostate specific antigen level, and prior ADT exposure with duration of ADT effect. Cancer 2008; 112(6): 1247-1253.
60. Keating NL, O'Malley J, McNaughton Collins M, Oh WK, Smith MR. Use of androgen deprivation therapy for metastatic prostate cancer in older men. BJU Int 2008 May; 101(9):1077-83.
61. Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayshi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, and Freedman MW. Inherited variation in the androgen pathway is associated with the efficacy of androgen deprivation therapy in men with prostate cancer. J Clin Oncol 2008; 26(6):842-7.
62. Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP. A Phase II study of mifepristone (RU-486) in castration resistant prostate cancer with correlative assessment of androgen-related hormones. BJU Int 2008 May; 101(9):1084-9.
63. Oh WK*, Sher DJ*, Jacobus S, Regan MM, Lee GS, Mantzoros C. Relationship between serum adiponectin and prostate cancer grade. Prostate 2008 Oct 1; 68(14):1592-8.
64. Sher DJ, Mantzoros C, Jacobus S, Regan MM, Lee GS, Oh WK. Absence of a relationship between steroid hormone levels and tumor grade in a prospective cohort of prostate cancer. Urology 2009 Feb; 73(2):356-61; discussion 361-2.
65. Simon RA, di Sant’Agnese PA, Huang L-S, Xu H, Yao JL, Yang Q, Liang S, Liu, J, Lee R, Cheng L, Oh WK, Palapattu G, Wei J, and Huang J. CD44 expression is a feature of prostatic small cell carcinoma and distinguishes it from its mimickers. Hum Pathol 2009 Feb; 40(2):252-8.
66. Choueiri TC, Xie W, D’Amico AV, Ross RW, Pomerantz M, Regan MM, Taplin ME, Kantoff PW, Sartor O, Oh WK. Time to PSA nadir independently predicts overall survival in metastatic hormone sensitive prostate cancer patients treated with androgen deprivation therapy. Cancer 2009 Mar 1; 115(5):981-7.
67. Mathew P, Thall PF, Wen S, Bucana C, Jones D, Horne E, Oh WK, Morris MJ, Lee Y-C, Logothetis CJ, Lin S-H, Fidler IJ,. Dynamic change in phosphorylated platelet-derived growth factor receptor in peripheral blood leucocytes following docetaxel therapy predicts progression-free and overall survival in prostate cancer. Br J Cancer 2008 Nov 4; 99(9):1426-32.
68. Oh WK*, Chan JM*, Xie W, Regan MM, Stampfer MJ, King IB, Abe M, Kantoff PW. Plasma selenium, manganese superoxide dismutase (SOD2) and intermediate or high risk prostate cancer. J Clin Oncol 2009 Aug 1;27(22):3577-83.
69. Michaelson MD, Regan MM, Oh WK, Kaufman DS, Olivier K, Michaelson SZ, Spicer B, Gurski C, Kantoff PW, Smith MR Phase 2 study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009; 20(5):913-920.
70. Pomerantz MM, Beckwith CA, Regan MM, Stacia K. Wyman SK, Petrovics G, Chen Y, Dorota J, Hawksworth DJ, Schumacher FR, Mucci L, Penney KL, Stampfer ML, Chan JA, Ardlie KG, Fritz BR, Parkin RK, Lin DW, Dyke M, Herman P, Lee S, Oh WK, Kantoff PW, Tewari M, McLeod DG, Srivastava S, Freedman ML. Evaluation of the 8q24 prostate cancer risk locus and MYC expression. Cancer Research 2009 Jul 1; 69(13):5568-74.
71. Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK. Activity of dustasteride plus ketoconazole in castrate-refractory prostate cancer after progression on ketoconazole alone. Clin Genitourin Cancer 2009 Oct 1;7(3):E90-E92.
72. Aggarwal R, Weinberg V, Small EJ, Oh W, Rushakoff R, Ryan CJ. The mechanism of action of estrogen in castrate resistant prostate cancer: clues from hormone levels. Clin Genitourin Cancer 2009 Oct 1;7(3):E71-E76.
73. Penney KL, Salinas CA, Pomerantz M, Schumacher FR, Beckwith CA, Lee GS, Oh WK, Sartor O, Ostrander EA, Kurth T, Ma J, Mucci L, Stanford JL, Kantoff PW, Hunter DJ, Stampfer MJ, Freedman ML. Evaluation of 8q24 and 17q risk loci and prostate cancer mortality. Clin Cancer Res 2009 May 1; 15(9):3223-30.
74. Regan MM, O’Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of 7 prospective clinical trials. Ann Oncol 2009 Jul 24 [Epub ahead of print]
75. Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl B, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott M, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor (VEGF)-targeted agents: Results from a large retrospective multicenter study. J Clin Oncol 2009 Dec 1;27(34):5794-9.
76. Duh MS, Ellison Dial E, Choueiri TK, Fournier AA, Antras L, Rodermund D, Neary MP, Oh WK. Cost implications of intravenous versus oral anti-angiogenic therapies in patients with advanced renal cell carcinoma: A retrospective claims database analysis. Curr Med Res Opin 2009; 25:2081-90.
77. Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg J. Activity of ketoconazole after taxane-based chemotherapy in castration resistant prostate cancer. BJU Int 2009 Oct 23. [Epub ahead of print]
78. Jia L, Gilad Landan G, Pomerantz M, Jaschek R, Herman P, Reich D, Yan C, Khalid O, Kantoff P, Oh W, Manak JR, Berman BP, Henderson BE, Frenkel B, Haiman CA, Freedman M, Tanay A, Coetzee GA. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genetics 2009 Aug;5(8):e1000597.
79. Choueiri TK, Duh MS, Clement J, Brick AJ, Rogers MJ, Kwabi C, Shah K, Percy G, Antràs L, Jayawant SS, Chen K, Wang ST, Luka A, Neary MP, McDermott D, Oh WK. Angiogenesis inhibitor therapies for metastatic renal cell carcinoma: effectiveness, safety, and treatment patterns in clinical practice based on medical chart review. BJU Int (In Press)
80. Jacobsen E, Chen JH, Schurko B, Benson C, Oh WK. Metastatic seminoma and grade I follicular lymphoma presenting concurrently in a supraclavicular lymph node. Cases J 2009 Aug 19;2:7273.
81. Oh WK, Landrum MB, Lamont EB, McNeil BJ, Keating NL. Does oral antiandrogen use before luteinizing hormone-releasing hormone therapy in patients with metastatic prostate cancer prevent clinical consequences of a testosterone flare? Urology 2010 Mar;75(3):642-7. Epub 2009 Dec 4.
82. Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Christopher W. Ryan CW, Mathew P, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP. Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone and dutasteride in asymptomatic castration resistant prostate cancer. Clin Cancer Res 2009 Nov 15;15(22):7099-105.
83. Abe M, Xie W, Regan MM, King I, Stampfer MJ, Kantoff PW, Oh WK, Chan J. Single nucleotide polymorphisms (SNPs) within the antioxidant defense system and association with aggressive prostate cancer. BJU Int (In Press)
84. Choueiri TK, Regan MM, Rosenberg JE, Oh WK, Clement J, Amato AM, McDermott D, Cho DC, Atkins MB, Signoretti S. Carbonic anhydrase IX and pathological features as predictors of outcome in patients with metastatic clear-cell renal cell carcinoma receiving vascular endothelial growth factor-targeted therapy. BJU Int. 2010 Mar 2. [Epub ahead of print]
85. Oh WK, Vargas R, Jacobus S, Leitzel K, Regan MM, Hamer P, Pierce K, Brown-Shimer K, Carney W, Ali SM, Kantoff PW, Lipton A. Elevated plasma TIMP-1 levels predict decreased survival in castration-resistant prostate cancer patients. Cancer (In Press)
86. Drzymalski DM, Oh WK, Werner L, Regan MM, Kantoff P, Tuli S. Predictors of survival in patients with prostate cancer and spinal metastasis. J Neurosurg (In Press)
Other Peer-Reviewed Publications:
87. Oh WK, Kantoff P. Prostate cancer. In: Skarin AT, ed. Hospital Physician: Oncology Board Review Manual. Wayne, NJ: Turner White Communications. 1997; 2(1):1-12.
88. Kantoff PW, Oh WK. Literature reviews. Journal of Oncology: Index and Reviews 1997; 1(2):6-10.
89. Oh WK, Kantoff PW. Hormone-refractory prostate cancer: current standards and future prospects. J Urol 1998; 160:1220-29.
90. Oh WK, Kantoff PW. Docetaxel (Taxotere)-based chemotherapy in hormone-refractory and locally advanced prostate cancer. Semin Oncol 1999; 26(suppl 17):49-54.
91. Reid P, Kantoff P, Oh WK. Antiandrogens in prostate cancer. Invest New Drugs 1999; 17:271-84.
92. Oh WK. Chemotherapy in advanced prostate cancer: a new option for therapy. Cancer (Suppl) 2000; 88(12):3015-21.
93. Oh WK. Anemia related to hormonal ablation in prostate cancer. The Prostate Journal 2001; 3(1):14-17.
94. Oh WK, George DJ, Kaufman DS, Moss K, Smith MR, Richie JP, Kantoff PW. Neoadjuvant docetaxel followed by radical prostatectomy in patients with high-risk localized prostate cancer: a preliminary report. Semin Oncol 2002; 28(4suppl15):40-4.
95. Oh WK, Small EJ. PC-SPES and prostate cancer. Urologic Clinics of North America 2002; 29(1):59-66, viii.
96. Oh WK. Secondary hormonal therapies in the treatment of prostate cancer. Urology 2002; 60(3Suppl1):87-92; discussion 93.
97. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'Amico AV, George DJ, Grossfeld GD, Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C; Second international conference on newer approaches to androgen deprivation therapy (ADT) in prostate cancer. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology 2002; 60(3 Suppl1):1-6.
98. Oh WK, Small EJ. Complementary and alternative therapies in prostate cancer. Semin Oncol 2002; 29(6):575-84.
99. Oh WK. The evolving role of estrogens in prostate cancer. Clin Prostate Cancer 2002; 1(2):81-89.
100. Oh WK. Predicting outcome in localized prostate cancer: How far have we come? Cancer Invest 2003; 21(3):487-8.
101. Yu EY, Oh WK. Neoadjuvant therapy in high risk localized prostate cancer. Curr Oncol Rep 2003; 5(3):250-7.
102. Oh WK. Neoadjuvant therapy prior to radical prostatectomy in high risk localized prostate cancer: Defining appropriate endpoints. Urol Oncol 2003; 21(3):229-34.
103. Oh WK. The evolving role of chemotherapy and other systemic therapies in managing
localized prostate cancer. J Urol 2003; 170(6):S28-S34.
104. Carroll PR, Benaron DA, Blackledge G, Coakley FV, D'Amico AV, Higano CS, Iversen P, Kattan M, Nanus DM, Nelson JB, Oh WK, Roach M 3rd, Sellers WR, Smith MR, McMann MC, Kantoff PW. Third international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol 2003; 170(6):S3-S5.
105. Nakabayashi M, Oh WK. Neoadjuvant and adjuvant chemotherapy for high risk localized prostate cancer. Curr Treat Options Oncol 2004; 5(5):349-55.
106. Oh WK, Halabi S, Kelly WK, Werner C, Godley PA, Vogelzang NJ, Shaw V, Small EJ. Synopsis of “A phase II study of estramustine, docetaxel and carboplatin with granulocyte-colony-stimulating-factor support in patients with hormone refractory prostate carcinoma: Cancer and Leukemia Group B 99813.” Am J Oncol Review 2004; 3(8):467-70.
107. Ross RW, Oh WK. Back to the Future: Is MVAC Still The Standard Of Care For Advanced Urothelial Cancer? Commentary on: “Docetaxel and cisplatin with granulocyte colony-stimulating factor versus MVAC with G-CSF in advanced urothelial carcinoma” Am J Oncol Review 2004; 3(8):493-6.
108. Carroll PB, Chan JML, D’Amico AV, Gelmann EP, Iversen P, Klotz L, Nelson JB, Nelson PS, Nelson WG, Oh WK, Rosen N, Rubin MA, Sandler H, Sellers WR, Smith MR, Xu J, McMann MC, Kantoff PW. Fourth international conference on innovations and challenges in prostate cancer: prevention, detection and treatment. J Urol 2004; 172:S3-S5.
109. Oh WK. An overview of chemotherapy trials in localized and recurrent nonmetastatic prostate cancer. J Urol 2004; 172: S37-S39.
110. Gilligan TD, Oh WK. “Prostate cancer” In: Goldmann DW (ed.). PIER, American College of Physicians. On-line module. Philadelphia, PA: American College of Physicians, 2004.
111. Nakabayashi M, Oh WK. Advances in prostate cancer treatment. Hosp Pharmacy Europe 2005; 21:74-5.
112. Oh WK. High-risk localized prostate cancer: integrating chemotherapy. Oncologist 2005; 10(suppl2):18-22.
113. Oh WK. “Case discussions” In: D’Amico AV, Kantoff PW, Montie JE (eds.). Report to the Nation of Prostate Cancer 2005: Focus on Advanced Disease. Santa Monica, CA: Prostate Cancer Foundation, 2005. pp. 37-48.
114. Oh WK. Docetaxel in hormone-refractory metastatic prostate cancer: a viewpoint by William K. Oh. Drugs. 2005; 65(16):2295-7.
115. Oh WK. Editorial comment on “Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer.” J Urol 2005; 174(5):1813
116. Nakabayashi M, Oh WK. Chemotherapy for high-risk localized prostate cancer. BJU Int 2006; 97(4):679-83.
117. Daskivich TD, Oh WK. Recent progress in hormonal therapy for advanced prostate cancer. Curr Opin Urol 2006; 16(3):173-8.
118. Gilligan TD, Oh WK, Kantoff PW. Carboplatin for stage I seminoma (letter). J Clin Oncol 2006; 24(18):2971-2; author reply e32-3.
119. Oh WK, Kantoff PW. Commentary on “A critical reevaluation of cytotoxic chemotherapy for the treatment of prostate cancer: 20 years later.” Oncology 2006; 20(8):867-8.
120. Sternberg CN, Krainer M, Oh WK, Bracarda S, Bellmunt J, Ozen H, Zlotta A, Beer TM, Oudard S, Rauchenwald M, Skonecza I, Borner MM, and Fitzgerald JM. The medical management of prostate cancer: a multidisciplinary team approach. BJU Int 2007; 99(1):22-7.
121. Oh WK, Tay MH, Huang JT. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007; 109(3):477-86.
122. Oh WK. Editorial comment on “A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.” J Urol 2007; 177(6):2145.
123. Kim J, Oh WK. Evaluating the role of platinum chemotherapy in the treatment of hormone-refractory prostate cancer. Am J Hemat Oncol 2007; 6(10):1-6.
124. Nakabayashi M, Oh WK. Treatment with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases: the risk of renal impairment. Am J Hemat Oncol 2007; 6(10): 7-11.
125. Pomerantz MM, Osman NY, Oh WK. Diagnosis and treatment of localized prostate cancer. Hospital Physician 2008: 44(3): 9-20.
126. Michaelson MD, Oh WK. “Treatment-related toxicity in men with testicular germ cell cancer” In: Up To Date, Version 16.1. Rose BD, ed. Up To Date, Waltham, MA, 2008.
127. Steele GS, Richie JP, Oh WK, Michaelson MD. “Clinical manifestations, diagnosis, staging of testicular cancer” In: Up To Date, Version 16.1. Rose BD, ed. Up To Date, Waltham, MA, 2008.
128. Michaelson MD, Oh WK. “Epidemiology of and risk factors for testicular cancer” In: Up To Date, Version 16.1. Rose BD, ed. Up To Date, Waltham, MA, 2008.
129. Oh WK, Richie JP. “Posttreatment follow-up for men with testicular cancer” In: Up To Date, Version 16.1. Rose BD, ed. Up To Date, Waltham, MA, 2008.
130. Michaelson MD, Oh WK. “Serum tumor markers in testicular cancer” In: Up To Date, Version 16.1. Rose BD, ed. Up To Date, Waltham, MA, 2008.
131. Beard CJ, Oh WK. “Treatment of stage II seminoma” In: Up To Date, Version 16.1. Rose BD, ed. Up To Date, Waltham, MA, 2008.
132. Oh WK. “Overview of the clinical presentation and treatment of testicular germ cell tumors. In: Up To Date, Version 16.1. Rose BD, ed. Up To Date, Waltham, MA, 2008.
133. Schurko B, Oh WK. Docetaxel chemotherapy remains the standard of care in castration-resistant prostate cancer. Nat Clin Pract Oncol 2008 Sep; 5(9):506-7.
134. Morris MJ, Basch EM, Wilding G, Hussain M, Carducci M, Higano C, Kantoff P, Oh WK, Small EJ, George D, Mathew P, Beer TM, Scher HI. Department of Defense Prostate Cancer Clinical Trials Consortium: A new instrument for prostate cancer clinical research. Clin Genitourin Cancer 2009 Jan; 7(1):51-7.
135. Bubley G, Garnick M, Oh WK, Taplin ME. Androgen-independent prostate cancer. Perspectives on Prostate Disease 2008: 2(3): 2-15.
136. Rosenberg J, Oh WK. What is the current status of second-line chemotherapy for castration-resistant prostate cancer? Nat Clin Pract Oncol 2008 Dec; 5(12):650-1.
137. Sher DJ, Oh WK. Serum testosterone and prostate cancer aggressiveness: our evolving understanding. Urology 2009 Feb; 73(2): 361-2.
138. Priolo C, Oh WK, Loda M. Novel therapeutic strategies in prostate cancer: establishing a stratification system for patient selection in targeted trials. IDrugs 2009 Mar; 12(3):165-8.
139. O’Donnell EK, Oh WK. Androgen deprivation therapy: A treatment option for localized prostate cancer? Am J Hemat Oncol 2009; 8(4):187-9.
140. Elfiky A, Oh WK, Choueiri TK. Health-related quality of life and symptom improvement for patients with metastatic renal cell carcinoma: Evaluating sunitinib and interferon alfa. Am J Hemat Oncol 2009; 8(4):200-1.
141. Schutz F, Oh WK. Neoadjuvant and adjuvant therapies for prostate cancer. Urol Clin North Am 2010 Feb;37(1):97-104.
142. Bellmunt J, Oh WK. Castration-resistant prostate cancer: new science and therapeutic prospects. Ther Adv Med Oncol (In Press)
Books:
143. Oh WK, editor. “Prostate Cancer.” Hematol Oncol Clin North Am 2006; Volume 20, Issue 4, Pages 773-1010.
144. Oh WK, Logue J, editors. Dana-Farber Cancer Institute Handbook Series: Prostate Cancer Edinburgh: Mosby, 2007.
145. Oh WK, Hu J, editors. Prostate Cancer: “Advances and Controversies in Prostate Cancer.” Urol Clin North Am Volume 37, Issue 1, Pages 1-148 (February 2010)
Chapters in Books:
146. Oh WK, Hurwitz M, D’Amico AA, Richie JP, Kantoff PW. “Neoplasms of the prostate” In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E III. (eds.) Cancer Medicine, 5th edition. Hamilton, Ontario: BC Decker, 2000. pp. 1559-1588
147. Oh WK. “Hematologic complications of prostate cancer” In: Kantoff PW, Carroll PR, D’Amico AV (eds.). Prostate Cancer: Principles and Practice. Philadelphia, PA: Lippincott William &Wilkins, 2002. pp. 601-611.
148. Oh WK, Garnick MB, Corless CL, Kantoff PW. “Cancers of the genitourinary tract” In: Skarin AT (ed.). Atlas of Diagnostic Oncology, 3rd Edition. London: Mosby-Wolfe, 2003. pp. 163-201.
149. Oh WK, Hurwitz M, D’Amico AA, Richie JP, Kantoff PW. “Chapter 111: Neoplasms of the prostate” In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III (eds.). Cancer Medicine, 6th edition. Hamilton, Ontario: BC Decker, 2003. pp. 1707-1740.
150. Oh WK. “Adrenal cancer” In: Furie B, Cassileth PA, Atkins MB, Mayer RJ (eds.). Clinical Practice of Hematology and Oncology: Presentations, Diagnosis and Treatment. Philadelphia, PA: Churchill Livingstone, 2003. pp. 1129-1132.
151. Tay MH, Oh WK. “Metastatic adenocarcinoma of the prostate” In: Richie JP, D’Amico AV (eds.). Urologic Oncology. Philadelphia PA: Elsevier Science, 2004. pp. 505-513.
152. Oh WK. “Neoadjuvant and adjuvant systemic therapy in high-risk localized prostate cancer” In: Perry MC (ed.). ASCO 2004 Educational Book, 40th Annual Meeting. Alexandria, VA: American Society of Clinical Oncology, 2004. pp. 243-247.
153. Dawson NA, Miguel RV, Oh WK, Saad F, Tay MH. “Recurrence” In: Bostwick DG, Crawford ED, Higano CS, Roach M (eds.). American Cancer Society’s Complete Guide to Prostate Cancer. Atlanta, GA: American Cancer Society, 2004. pp. 277-292.
154. Klein EA, Sandler HM, Messing EM, Kelly WK, Oh WK. “Integration of local and systemic therapies for high-risk newly diagnosed prostate cancer” In: Perry MC (ed.).ASCO 2005 Educational Book, 41st Annual Meeting. Alexandria, VA: American Society of Clinical Oncology, 2005. pp. 352-60.
155. Tay MH, Nakabayashi M, Oh WK. “Management of hormone refractory prostate cancer” In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM (eds.). Textbook of Genitourinary Oncology, 3rd edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2006. pp. 341-354.
156. Ross RW, Oh WK, Hurwitz M, D’Amico AA, Richie JP, Kantoff PW. “Neoplasms of the prostate” In: Kufe DW, Pollock RE, Weichselbaum RR, Bast RC, Gansler TS, Holland JF, Frei E III (eds.). Cancer Medicine, 7th edition. Hamilton, Ontario: BC Decker, 2006. pp. 1431-1462.
157. Ross RW, Nakabayashi M, Garnick MB, Corless CL, Kantoff PW, Oh WK. “Prostate Cancer: epidemiology, histology, diagnosis and staging” In: Oh WK, Logue J, editors. Dana-Farber Cancer Institute Handbook Series: Prostate Cancer Edinburgh: Mosby, 2007. pp. 21-56.
158. Nakabayashi M, Ross RW, Oh WK. “Prostate cancer therapy” In: Oh WK, Logue J, editors. Dana-Farber Cancer Institute Handbook Series: Prostate Cancer. Edinburgh: Mosby, 2007. pp. 57-91
159. Oh WK, Kim J. “Chemotherapy for prostate cancer.” In: Gulley JL, Dahut WL, Moul JW, Sandler HM, eds. Prostate Cancer: A Clinical Guide. Philadelphia: Lippincott, Williams & Wilkins; 2008. Chapter 16. pp. 160-166.
160. Pomerantz MP, Elfiky AA, Katz LM, Oh WK. “Genitourinary Cancers: Prostate, Kidney, Bladder and Testis” In: Loscalzo J, Singh A, eds. Brigham Intensive Review of Internal Medicine New York: Oxford University Press (In Press)
161. Brick AJ, Niu J, Huang J, Oh WK. Platinum agents. In Figg WD, Chau C, Small EJ, eds. Drug Management of Prostate Cancer. Totowa NJ: Humana Press (In Press)
162. Oh WK, Hu JC. Preface: Advances and Controversies in Prostate Cancer. Urol Clin North Am. 2010 Feb;37(1):xiii.
163. Seng S, Nakabayashi M, Oh WK. “Management of hormone refractory prostate cancer” In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM (eds.). Textbook of Genitourinary Oncology, 4th edition. Philadelphia, PA: Lippincott Williams & Wilkins. (In Press)
Galsky MD, Darling M, Hecht J, Salgia R. Case 1: small bowel obstruction due to metastatic lung cancer. Journal of Clinical Oncology. 2000; 18:227-228.
Kemeny N, Galsky M. Metastatic colorectal cancer treated with 5-fluorouracil/leucovorin/ irinotecan and celecoxib. Case Studies in Colorectal Cancer. 2002:1;1-6.
Kemeny N, Galsky M. Hepatic artery infusion for liver metastases. Seminars in Colon and Rectal Surgery. 2002;13: 293-304.
Smaletz O, Galsky M, Scher HI, et al. Pilot Study of Epothilone B Analogue (BMS-247550) and Estramustine Phosphate in patients with progressive metastatic prostate cancer following castration. Ann Oncol. 2003;14:1518-2
Galsky M, Kelly WK. The development of differentiation agents for the treatment of prostate cancer. Semin Oncol. 2003;30:689-97.
Galsky M, Kelly WK. The use of nomograms for predicting survival in patients with castrate prostate cancer. Urology. 2003;62 Suppl 1:119-27.
Galsky M, Herr H, Bajorin D. The Integration of Chemotherapy and Surgery for Bladder Cancer. The Journal of the National Comprehensive Cancer Network. 2005: 5:45-51.
Galsky MD. The role of taxanes in the management of bladder cancer. Oncologist. 2005 Nov;10(10):792-8.
Galsky M, Small E, Oh W, et al. Multi-institutional Randomized Phase II Trial of the Epothilone B Analogue Ixabepilone (BMS-247550) with or without Estramustine Phosphate in Patients with Progressive Castrate Metastatic Prostate Cancer. Journal of Clinical Oncology. 2005;23:1439-46.
Ross RW, Manola J, Hennessy K, Galsky M, et al, Prognostic Significance of Baseline Reverse Transcriptase-PCR for Prostate-Specific Antigen in Men with Hormone Refractory Prostate Cancer Treated with Chemotherapy. Clin Cancer Res. 2005 Jul 15;11(14):5195-8.
Galsky M, Scher H. Bladder Cancer "Adjuvant-Lite": Tastes Great (works as well) and Less Filling (less toxic)? Journal of Clinical Oncology. 2005 Aug 1;23(22):4823-6.
Galsky MD, Sonpavde G, Hutson TE, Current Management of Bladder Cancer. US Oncological Disease 2006 - Issue 2
Rosenberg JE, Galsky MD, Rohs NC, Weinberg VK, Oh WK, Kelly WK, Small EJ. A retrospective evaluation of second-line chemotherapy response in hormone-refractory prostate carcinoma. Cancer. 2006 Jan 1;106(1):58-62.
Slovin F, Galsky MD, Busam K, Violaceous exanthem as a manifestation of metastatic prostate cancer in skin. Urology. 2006 Feb;67(2):420.
Dash A, Galsky MD, Vickers AJ, The impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder, Cancer, 2006 Aug 1;107(3):506-13.
Hutson TE, Sonpavde G, Galsky MD. Targeting Growth Factor and Antiangiogenic Pathways in Clear-Cell Renal Cell Carcinoma: Rationale and Ongoing Trials. Clin Genitourin Cancer. 2006 Dec;5 Suppl 1:S31-9.
Galsky MD, Iasonos A, Mironov S, et al. Prospective Trial of Ifosfamide, Paclitaxel, and Cisplatin (ITP) in Patients with Advanced NON-transitional Cell Carcinomas of the Urothelial Tract. Urology. 2007 Feb;69(2):255-9.
Galsky MD, Iasonos A, Mironov S, et al. Phase II Trial of Dose-Dense Doxorubicin plus Gemcitabine followed by Paclitaxel plus Carboplatin in Patients with Advanced/Metastatic Urothelial Carcinoma and Impaired Renal Function. Cancer, 2007 Feb 1;109(3):549-55.
Galsky MD, Kelly WK. High-dose bicalutamide after radiotherapy for locally advanced prostate cancer: a standard of care? Nat Clin Pract Urol. 2007 Mar;4(3):134-5.
Galsky MD, Iasonos A, Mironov S, et al. Phase II Trial of Pemetrexed as Second-Line Therapy in Patients with Metastatic Urothelial Carcinoma. Investigational New Drugs, 2007 Jun;25(3):265-270.
Galsky MD, Vogelzang, NJ. Outcomes and prognosis in advanced renal cell carcinoma. Expert Rev Anticancer Ther. 2007 Jun;7(6):839-45.
Sonpavde G, Chi KN, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Berry WR, Kadmon D. Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer. Cancer. 2007 Dec 15;110(12):2628-39.
Sonpavde G, Ross R, Powles T, Sweeney CJ, Hahn N, Hutson TE, Galsky MD, Lerner SP, Sternberg CN. Novel agents for muscle-invasive and advanced urothelial cancer. BJU Int. 2008 Apr;101(8):937-43.
Galsky MD, Eisenberger M, Moore-Cooper S, et al. Phase I Trial of the Prostate-Specific Membrane Antigen–Directed Immunoconjugate, MLN2704, in Patients with Progressive Metastatic Castration–Resistant Prostate Cancer, Journal of Clinical Oncology. 2008 May 1;26(13):2147-54.
Sonpavde G, Hutson TE, Galsky MD Current optimal chemotherapy for advanced urothelial cancer. Expert Rev Anticancer Ther. 2008 Jan;8(1):51-61.
Galsky MD, Zaks T, Hassani H, Vocila L, Sonpavde G, Hutson TE, Von Hoff DD. Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs. 2010 Apr;28(2):194-8.
Sonpavde G, Galsky MD, Hutson TE, Von Hoff DD. Patient Selection for Phase II Trials. Am J Clin Oncol. 2009 Apr;32(2):216-9.
Young LR, Franz DN, Nagarkatte P, Fletcher CD, Wikenheiser-Brokamp KA, Galsky MD, Corbridge TC, Lam AP, Gelfand MJ, McCormack FX. Utility of FDG-PET in Sporadic and Tuberous Sclerosis Associated Lymphangioleiomyomatosis. Chest. 2009 Sep;136(3):926-33.
Galsky MD, Simon K, Sonpavde G, Hutson TE, Fleming M, Kondagunta GV, Berry W.
Ketoconazole retains activity in patients with docetaxel-refractory prostate cancer. Ann Oncol. 2009 May;20(5):965-6.
Sonpavde G, Periman PO, Bernold D, Weckstein D, Fleming MT, Galsky MD, Berry WR, Zhan F, Boehm KA, Asmar L, Hutson TE. Sunitinib malate for metastatic castration-resistant prostate cancer following docetaxel-based chemotherapy. Ann Oncol. 2010 Feb;21(2):319-24.
Sonpavde G, Aparicio AM, Zhan F, North B, Delaune R, Garbo LE, Rousey SR, Weinstein RE, Xiao L, Boehm KA, Asmar L, Fleming MT, Galsky MD, Berry WR, Von Hoff DD. Azacitidine favorably modulates PSA kinetics correlating with plasma DNA LINE-1 hypomethylation in men with chemonaïve castration-resistant prostate cancer. Urol Oncol. 2009 Dec 1. [Epub ahead of print]
Galsky MD, Vogelzang NJ. Docetaxel-based combination therapy for castration-resistant prostate cancer. Ann Oncol. 2010 Mar 29. [Epub ahead of print]
Sonpavde G, Sternberg CN, Rosenberg JE, Hahn NM, Galsky MD, Vogelzang NJ. Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium. Lancet Oncol. 2010 May 25. [Epub ahead of print]
Textbooks:
Galsky M, Bajorin D. Chemotherapy for Metastatic Bladder In: Vogelzang NJ, Scardino PT, Shipley WU, Debruyne FMJ, Linehan WM, editors. Comprehensive Textbook of Genitourinary Oncology, Third Edition. Lippincott Williams & Wilkins, 2005.
Galsky M, Bajorin D. Chemotherapy for Bladder Cancer In: Waxman J, editor. Urological Oncology: Science and Treatment. Springer-Verlag, 2005.
Contributing author: Hematology and Oncology Pearls, Danso M, Basch E, editors. Elseveir-Mosby, 2005.
Galsky M, Bajorin D. Bladder Cancer In: Schrier R, editor. Diseases of the Kidney and Urinary Tract, Eighth Edition, Lippincott Williams & Wilkins, 2006.
Galsky M, Bajorin D. Management of Metastatic Bladder Cancer In: Nargund VH, Raghavan D, Sandler HM, editors. Urological Oncology. 2006.
Galsky M, Bajorin D. Chemotherapy for Bladder Cancer In: Waxman J, editor. Urological cancers in clinical practice (pocket book).Springer-Verlag. 2006.
Galsky M. Dx/Rx: Genitourinary Oncology – Cancer of the Kidneys, Bladder, and Testis; Shah M, editor. Jones and Bartlett Publishers. 2008.
Galsky M. Everything You Need to Know About Cancer In Language You Can Actually Understand. Jones and Bartlett Publishers. 2009.
The Tisch Cancer Institute established the Genitourinary (GU) Cancer Biorepository in 2010 to develop a repository for biomarker development through collection of liquid and tissue specimens from cancer patients at multiple points during their cancer therapy. As of June 2012, 500 patients have been consented to this project.
CLINICAL DATA: All patients with a GU cancer diagnosis irrespective of tissue specimen availability are approached for participation. Patient medical records are reviewed and data points relevant to cancer diagnosis, disease progression, and treatment information are entered into a clinical research database. Updates occur after each clinic visit.
LIQUID SPECIMENS: A blood draw is performed at standard-of-care (SOC) clinic visits and resulting liquid specimens frozen at -80C for future research use.
TISSUE SPECIMENS: If a patient is scheduled for an SOC surgical procedure, research samples are isolated from any excised tissue for both formalin-fixation and freezing at -80C for future research use.
LINKAGE BETWEEN CLINICAL DATA AND SPECIMENS: All collected specimens are recorded in a specimen database which is data-linked to the clinical research database. These clinically annotated specimens are readily available to investigators who wish to do cancer research.
If you are interested in gaining access to our clinically annotated GU cancer specimens, please review and complete the Specimen Request Form.
To find our clinical trials please go here: http://icahn.mssm.edu/research/clinical-trials